ResMed Director Peter Farrell Plans Modest Insider Share Sale Under Rule 144

The latest update is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).

ResMed director Peter C. Farrell has filed notice of a proposed sale of 2,000 common shares under Rule 144, with Merrill Lynch acting as the broker and the shares listed on the NYSE. The planned sale, part of a trading plan adopted in August 2025, follows Farrell’s prior sales of 6,000 shares over the past three months, signaling continued insider portfolio diversification but on a relatively small scale versus ResMed’s total shares outstanding.

Farrell acquired the shares to be sold through the exercise of stock options paid in cash, aligning with typical executive compensation practices at large listed companies. In signing the notice, he affirmed that he is not aware of undisclosed material adverse information about ResMed, which may reassure investors that the transactions are routine rather than a sign of operational concerns.

The most recent analyst rating on (AU:RMD) stock is a Hold with a A$39.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. is a U.S.-based medical device company focused on sleep and respiratory care, including equipment and software that help manage sleep apnea and other chronic respiratory conditions. The company serves patients, healthcare providers, and sleep clinics globally through devices, masks, and digital health solutions.

Average Trading Volume: 1,108,534

Technical Sentiment Signal: Hold

Current Market Cap: A$53.4B

See more data about RMD stock on TipRanks’ Stock Analysis page.